IMMUNITYBIO, INC. (IBRX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value (m); Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | (m) | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 1.67B USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | (m) | Accounts Payable, Current |
| Total deferred revenue | (m) | Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | (m) | Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Deferred revenue due after one year | (m) | Deferred Revenue, Noncurrent · Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | 510.00K USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $38.71M |
| Finance lease obligations | $254.00K |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | (m) | (m) | $1.67B | (m) | (m) | (m) | $510.00K | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | (m) | $1.52B | (m) | (m) | (m) | $472.00K | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | $1.00B | (m) | (m) | (m) | $424.00K | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | $1.04B | (m) | (m) | (m) | $702.00K | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | $971.89M | (m) | (m) | (m) | $710.00K | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | $894.24M | (m) | (m) | (m) | $370.00K | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | $871.06M | (m) | (m) | (m) | $639.00K | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | $1.11B | (m) | (m) | (m) | $705.00K | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | $1.14B | (m) | (m) | (m) | $704.00K | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | $1.09B | (m) | (m) | (m) | $1.28M | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | $1.09B | (m) | (m) | (m) | $1.11M | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $843.06M | (m) | (m) | (m) | $467.00K | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $936.41M | (m) | (m) | (m) | $473.00K | (m) |
| 2023-03-31 | (m) | $33.57M | (m) | (m) | (m) | $875.12M | (m) | (m) | (m) | $462.00K | (m) |
| 2022-12-31 | (m) | $21.02M | (m) | (m) | (m) | $812.18M | (m) | (m) | (m) | $457.00K | (m) |
| 2022-09-30 | (m) | $20.24M | (m) | (m) | (m) | $782.02M | (m) | (m) | (m) | $569.00K | (m) |
| 2022-06-30 | (m) | $18.05M | (m) | (m) | (m) | $739.69M | (m) | (m) | (m) | $290.00K | (m) |
| 2022-03-31 | (m) | $9.83M | (m) | (m) | (m) | $727.14M | (m) | (m) | (m) | $288.00K | (m) |
| 2021-12-31 | (m) | $11.42M | (m) | (m) | (m) | $712.82M | (m) | (m) | (m) | $249.00K | (m) |
| 2021-09-30 | (m) | $15.12M | $145.00K | (m) | (m) | $404.37M | (m) | (m) | (m) | $905.00K | (m) |
| 2021-06-30 | (m) | $19.15M | $217.00K | (m) | (m) | $404.89M | (m) | (m) | (m) | $920.00K | (m) |
| 2021-03-31 | (m) | $20.10M | $263.00K | (m) | (m) | $394.76M | (m) | (m) | (m) | $891.00K | (m) |
| 2020-12-31 | (m) | $4.10M | (m) | $1.44M | (m) | $34.47M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.16M | (m) | $2.30M | (m) | $31.91M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $3.97M | (m) | $3.40M | (m) | $26.51M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.15M | (m) | $3.61M | (m) | $24.43M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $1.75M | (m) | $3.98M | (m) | $22.44M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $2.12M | (m) | $4.29M | (m) | $24.25M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.93M | (m) | $3.08M | (m) | $24.43M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $2.80M | (m) | $3.12M | (m) | $40.45M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.79M | (m) | $1.67M | (m) | $35.94M | (m) | (m) | (m) | $0.00 | (m) |
| 2018-09-30 | (m) | $3.52M | (m) | $1.92M | (m) | $39.55M | (m) | (m) | (m) | $24.00K | (m) |
| 2018-06-30 | (m) | $5.50M | (m) | $1.37M | (m) | $29.80M | (m) | (m) | (m) | $44.00K | (m) |
| 2018-03-31 | (m) | $3.57M | (m) | $1.30M | (m) | $29.48M | (m) | (m) | (m) | $65.00K | (m) |
| 2017-12-31 | (m) | $5.87M | (m) | $1.37M | $89.00K | $31.60M | (m) | (m) | $166.00K | $89.00K | $0.00 |
| 2017-09-30 | (m) | $9.48M | (m) | $1.36M | (m) | $40.03M | (m) | (m) | (m) | $341.00K | (m) |
| 2017-06-30 | (m) | $4.27M | (m) | $1.13M | (m) | $48.70M | (m) | (m) | (m) | $370.00K | (m) |
| 2017-03-31 | (m) | $4.28M | (m) | $939.00K | $216.00K | $25.31M | (m) | (m) | $182.00K | $216.00K | $0.00 |
| 2016-12-31 | (m) | $4.04M | (m) | $891.00K | $240.00K | $24.08M | (m) | (m) | $187.00K | $240.00K | $0.00 |
| 2016-09-30 | (m) | $2.25M | (m) | $224.00K | $22.00K | $21.52M | (m) | (m) | $192.00K | $22.00K | $0.00 |
| 2016-06-30 | (m) | $3.30M | (m) | $291.00K | $26.00K | $15.58M | (m) | (m) | $197.00K | $26.00K | $0.00 |
| 2016-03-31 | (m) | $1.10M | (m) | $363.00K | (m) | $12.93M | (m) | (m) | $203.00K | (m) | $0.00 |
| 2015-12-31 | (m) | $2.08M | (m) | $136.00K | (m) | (m) | (m) | (m) | $228.00K | (m) | $0.00 |
| 2015-09-30 | (m) | $4.95M | (m) | (m) | (m) | $7.26M | (m) | $235.00K | (m) | (m) | (m) |
| 2015-06-30 | (m) | $3.18M | (m) | (m) | (m) | $6.04M | (m) | $241.00K | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.13M | (m) | (m) | (m) | $2.40M | (m) | $521.00K | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |